What side effects are associated with this type of intervention?

Common treatments for psoriasis include topical therapies, phototherapy, and systemic agents such as biologics and oral medications. Topical treatments can cause skin irritation and dryness. Phototherapy may lead to erythema, pruritus, and an increased risk of skin cancer with prolonged use. Systemic treatments, including biologics like TNF-alpha inhibitors, can have side effects such as increased risk of infections, injection site reactions, and potential cardiovascular risks. Oral medications like methotrexate and cyclosporine can cause liver toxicity, renal impairment, and hypertension. While specific data on treatments targeting neural systems like DiNaMo components are limited, these common treatments provide a broad overview of potential side effects.

What prior FDA approvals exist?

FDA-approved treatments for psoriasis include biologic agents such as TNF-alpha inhibitors (e.g., etanercept), IL-12/23 inhibitors (e.g., ustekinumab), IL-17A inhibitors (e.g., secukinumab and ixekizumab), and IL-23 inhibitors (e.g., risankizumab). These treatments primarily target the immune system to reduce inflammation and slow disease progression. While the context does not mention treatments specifically targeting neural systems like the DiNaMo components, the focus remains on modulating immune responses to manage psoriasis symptoms.

What other types of research exist?

Promising novel alternatives to DiNaMo components for psoriasis treatment in 2024 include Janus kinase inhibitors (e.g., Tofacitinib) and glucagon-like peptide-1 agonists (e.g., Liraglutide). These therapies target different pathways and have shown benefits in managing psoriasis.

← Back to Search

Behavioural Intervention

CT-100-004-A Psoriasis for Atopic Dermatitis

N/A

Waitlist Available

Research Sponsored by Click Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Itch NRS ≥ 4 during screening

Aged 18 years or older

Must not have

Planning the introduction of new therapies during the 7-week study period

Anticipating a change in current pharmacological or psychotherapy treatment regimen during the 7-week study period

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 5

Summary

This trial tests a software to help patients with skin conditions like atopic dermatitis and psoriasis by improving brain functions related to various aspects of health.

Who is the study for?

This trial is for individuals with skin conditions like atopic dermatitis, eczema, or psoriasis. Participants should be interested in trying a digital intervention aimed at reducing scratching behavior.

What is being tested?

The study tests two versions of CT-100, a software platform with interactive components designed to disrupt scratching by targeting neural systems related to various sensory and cognitive processes.

What are the potential side effects?

Since this is a digital intervention involving software-based therapeutic components, traditional physical side effects are not expected. Users may experience eye strain or mental fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My itchiness level is 4 or higher.

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I plan to start new treatments within the next 7 weeks.

Select...

I plan to change my current medication or therapy within the next 7 weeks.

Select...

I currently have a skin infection.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 5

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 5

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 5 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Dermatology Life Quality Index

Change in Peak Pruritus Numerical Rating Scale

Change in Quality of Life symptoms

+3 more

Secondary study objectives

Frequency of Adverse Events

Frequency of Serious Adverse Events

Severity of Adverse Events

+1 more

Trial Design

4Treatment groups

Experimental Treatment

Placebo Group

Group I: CT-100-004-A PsoriasisExperimental Treatment1 Intervention

Group II: CT-100-004-A Atopic DermatitisExperimental Treatment1 Intervention

Group III: CT-100-004-B PsoriasisPlacebo Group1 Intervention

Group IV: CT-100-004-B Atopic DermatitisPlacebo Group1 Intervention

0 / 5Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for psoriasis include TNF-alpha inhibitors, methotrexate, cyclosporine, and phototherapy. TNF-alpha inhibitors work by blocking tumor necrosis factor-alpha, a cytokine involved in systemic inflammation, thereby reducing the inflammatory response in psoriasis. Methotrexate inhibits dihydrofolate reductase, leading to reduced DNA synthesis and cell proliferation, which helps control the rapid skin cell turnover in psoriasis. Cyclosporine suppresses the immune system by inhibiting calcineurin, reducing T-cell activation and subsequent inflammation. Phototherapy uses ultraviolet light to slow skin cell growth and reduce scaling and inflammation. These treatments are crucial for psoriasis patients as they target the underlying inflammatory and immune processes, providing symptom relief and improving quality of life. While DiNaMo components focus on neural system modulation, the common psoriasis treatments primarily target immune and inflammatory pathways, highlighting the multifaceted approach needed for effective management.

A systematic review of evidence based treatments for lichen simplex chronicus.